The role of CD154 in haematopoietic development

Thrombosis and Haemostasis

Volumn 104, Issue 4, 2010, Pages 693-701

  Seijkens, Tom ^a   Engel, David ^a   Tjwa, Marc ^b,c   Lutgens, Esther ^a,d  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

CD154; CD40; Haematopoiesis; Lymphopoiesis

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND;

AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL DIFFERENTIATION; CELL LINEAGE; DENDRITIC CELL; DRUG TARGETING; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE RESPONSE; LYMPHOMA; LYMPHOPOIESIS; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; THYMOCYTE;

ANIMALS; AUTOIMMUNE DISEASES; CD40 LIGAND; CELL LINEAGE; HEMATOLOGIC NEOPLASMS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNE SYSTEM; LYMPHOPOIESIS;

EID: 77958117980     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-03-0174     Document Type: Review

References (121)

1. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994;76: 959-962. (Pubitemid 24106376)
2. Villa A, Notarangelo LD, Di Santo JP, et al. Organization of the human CD40L gene: implications for molecular defects in X chromosome-linked hyper-IgM syndrome and prenatal diagnosis. Proc Natl Acad Sci USA 1994; 91: 2110-2114.
3. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58: 4-43.
4. Brenner B, Koppenhoefer U, Grassme H, et al. Evidence for a novel function of the CD40 ligand as a signalling molecule in T-lymphocytes. FEBS Lett 1997; 417: 301-306. (Pubitemid 27511609)
5. El Fakhry Y, Alturaihi H, Diallo D, et al. Critical role of lipid rafts in CD154-mediated T cell signaling. Eur J Immunol 2009; 40: 770-779.
6. Andre P, Prasad KS, Denis CV, et al. CD40L stabilizes arterial thrombi by a beta3 integrin - dependent mechanism. Nat Med 2002; 8: 247-252. (Pubitemid 34250102)
7. Foy TM, Aruffo A, Bajorath J, et al. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol 1996; 14: 591-617. (Pubitemid 26130658)
8. Andre P, Nannizzi-Alaimo L, Prasad SK, et al. Platelet-derived CD40L: the switchhitting player of cardiovascular disease. Circulation 2002; 106: 896-899. (Pubitemid 34925319)
9. Matthies KM, Newman JL, Hodzic A, Wingett DG. Differential regulation of soluble and membrane CD40L proteins in T cells. Cell Immunol 2006; 241: 47-58. (Pubitemid 44444899)
10. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111. (Pubitemid 36337321)
11. Cipollone F, Ferri C, Desideri G, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003; 108: 2776-2782. (Pubitemid 37498980)
12. Cipollone F, Chiarelli F, Davi G, et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005; 48: 1216-1224. (Pubitemid 40909659)
13. Engel D, Seijkens T, Poggi M, et al. The immunobiology of CD154-CD40-TRAF interactions in atherosclerosis. Semin Immunol 2009; 21: 308-312.
14. Hristov M, Gumbel D, Lutgens E, et al. Soluble CD40 ligand impairs the function of peripheral blood angiogenic outgrowth cells and increases neointimal formation after arterial injury. Circulation 2010; 121: 315-324.
15. Lievens D, Eijgelaar WJ, Biessen EA, et al. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost 2009; 102: 206-214.
16. Wang Y, Kelly CG, Karttunen JT, et al. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Immunity 2001; 15: 971-983. (Pubitemid 34075377)
17. Brodeur SR, Angelini F, Bacharier LB, et al. C4b-binding protein (C4BP) activates B cells through the CD40 receptor. Immunity 2003; 18: 837-848. (Pubitemid 36776431)
18. Lazarevic V, Myers AJ, Scanga CA, et al. CD40, but not CD40L, is required for the optimal priming of T cells and control of aerosol M. tuberculosis infection. Immunity 2003; 19: 823-835. (Pubitemid 37542303)
19. Mehlhop PD, van de Rijn M, Brewer JP, et al. CD40L, but not CD40, is required for allergen-induced bronchial hyperresponsiveness in mice. Am J Respir Cell Mol Biol 2000; 23: 646-651.
20. Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med 1999; 5: 1313-1316.
21. Lutgens E, Cleutjens KB, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci USA 2000; 97: 7464-7469. (Pubitemid 30431486)
22. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-1103.
23. Peters AL, Stunz LL, Bishop GA. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 2009; 21: 293-300.
24. Lutgens E, Poggi M, Weber C. CD40L-CD40 fuel ignites obesity. Thromb Haemost 2010;103: 694-695.
25. Missiou A, Wolf D, Platzer I, et al. CD40L induces inflammation and adipogenesis in adipose cells - a potential link between metabolic and cardiovascular disease. Thromb Haemost 2010; 103: 788-796.
26. Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394: 200-203. (Pubitemid 28325976)
27. Lutgens E, Lievens D, Beckers L, et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207: 391-404.
28. Donners MM, Beckers L, Lievens D, et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood 2008; 111: 4596-4604.
29. Hassan GS, Merhi Y, Mourad WM. CD154 and its receptors in inflammatory vascular pathologies. Trends Immunol 2009; 30: 165-172.
30. de Fougerolles AR, Koteliansky VE. Regulation of monocyte gene expression by the extracellular matrix and its functional implications. Immunol Rev 2002; 186: 208-220.
31. Qiang YW, Kitagawa M, Higashi M, et al. Activation of mitogen-activated protein kinase through alpha5/beta1 integrin is required for cell cycle progression of B progenitor cell line, Reh, on human marrow stromal cells. Exp Hematol 2000; 28: 1147-1157.
32. Leveille C, Bouillon M, Guo W, et al. CD40 ligand binds to alpha5beta1 integrin and triggers cell signaling. J Biol Chem 2007; 282: 5143-5151. (Pubitemid 47093769)
33. Zirlik A, Maier C, Gerdes N, et al. CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1. Circulation 2007; 115: 1571-1580. (Pubitemid 46648642)
34. Prasad KS, Andre P, He M, Bao M, Manganello J, Phillips DR. Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 2003; 100: 12367-12371. (Pubitemid 37271566)
35. Notarangelo LD, Hayward AR. X-linked immunodeficiency with hyper-IgM (XHIM). Clin Exp Immunol 2000; 120: 399-405.
36. Winkelstein JA, Marino MC, Ochs H, et al. The X-linked hyper-IgM syndrome: clinical and immunologic features of 79 patients. Medicine (Baltimore) 2003; 82: 373-384. (Pubitemid 37445041)
37. Imai K, Shimadzu M, Kubota T, et al. Female hyper IgM syndrome type 1 with a chromosomal translocation disrupting CD40LG. Biochim Biophys Acta 2006; 1762: 335-340. (Pubitemid 43172849)
38. Schwarz BA, Bhandoola A. Trafficking from the bone marrow to the thymus: a prerequisite for thymopoiesis. Immunol Rev 2006; 209: 47-57.
39. Dunn RJ, Luedecker CJ, Haugen HS, et al. Thymic overexpression of CD40 ligand disrupts normal thymic epithelial organization. J Histochem Cytochem 1997; 45: 129-141.
40. Galy AH, Spits H. CD40 is functionally expressed on human thymic epithelial cells. J Immunol 1992; 149: 775-782.
41. Zhou L, Chong MM, Littman DR. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009; 30: 646-655.
42. Barrett NA, Austen KF. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity 2009; 31: 425-437.
43. Soroosh P, Doherty TA. Th9 and allergic disease. Immunology 2009; 127: 450-458.
44. Pilon C, Levast B, Meurens F, et al. CD40 engagement strongly induces CD25 expression on porcine dendritic cells and polarizes the T cell immune response toward Th1. Mol Immunol 2009; 46: 437-447.
45. Jenkins SJ, Perona-Wright G, MacDonald AS. Full development of Th2 immunity requires both innate and adaptive sources of CD154. J Immunol 2008; 180: 8083-8092.
46. Straw AD, MacDonald AS, Denkers EY, et al. CD154 plays a central role in regulating dendritic cell activation during infections that induce Th1 or Th2 responses. J Immunol 2003; 170: 727-734.
47. Perona-Wright G, Jenkins SJ, O'Connor RA, et al. A pivotal role for CD40-mediated IL-6 production by dendritic cells during IL-17 induction in vivo. J Immunol 2009; 182: 2808-2815.
48. Iezzi G, Sonderegger I, Ampenberger F, et al. CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4+ T cells. Proc Natl Acad Sci USA 2009; 106: 876-881.
49. Guiducci C, Valzasina B, Dislich H, et al. CD40/CD40L interaction regulates CD4+CD25+ T reg homeostasis through dendritic cell-produced IL-2. Eur J Immunol 2005; 35: 557-567. (Pubitemid 40331332)
50. Smook ML, Heeringa P, Damoiseaux JG, et al. Leukocyte CD40L deficiency affects the CD25(+) CD4 T cell population but does not affect atherosclerosis. Atherosclerosis 2005; 183: 275-282. (Pubitemid 41579278)
51. Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003; 74: 961-965. (Pubitemid 38040316)
52. Spence PJ, Green EA. Foxp3+ regulatory T cells promiscuously accept thymic signals critical for their development. Proc Natl Acad Sci USA 2008; 105: 973-978.
53. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3: 253-257.
54. Schuurhuis DH, Fu N, Ossendorp F, et al. Ins and outs of dendritic cells. Int Arch Allergy Immunol 2006; 140: 53-72.
55. Blom B, Spits H. Development of human lymphoid cells. Annu Rev Immunol 2006; 24: 287-320.
56. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 2007; 7: 19-30.
57. Naik SH. Demystifying the development of dendritic cell subtypes, a little. Immunol Cell Biol 2008; 86: 439-452. (Pubitemid 351948216)
58. Flores-Romo L, Bjorck P, Duvert V, et al. CD40 ligation on human cord blood CD34+ hematopoietic progenitors induces their proliferation and differentiation into functional dendritic cells. J Exp Med 1997; 185: 341-349. (Pubitemid 27078290)
59. Ouaaz F, Arron J, Zheng Y, et al. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 2002; 16: 257-270. (Pubitemid 34211965)
60. Kobayashi T, Walsh PT, Walsh MC, et al. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 2003; 19: 353-363. (Pubitemid 37153412)
61. Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997; 186: 2075-2080. (Pubitemid 28013694)
62. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994; 180: 83-93. (Pubitemid 24181058)
63. Santiago-Schwarz F, Belilos E, Diamond B, et al. TNF in combination with GMCSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. J Leukoc Biol 1992; 52: 274-281.
64. Zhou M, Gu L, Holden J, et al. CD40 ligand upregulates expression of the IL-3 receptor and stimulates proliferation of B-lineage acute lymphoblastic leukemia cells in the presence of IL-3. Leukemia 2000; 14: 403-411. (Pubitemid 30142863)
65. Fu J, Liu Y, Zhang X. CD40 ligandization promotes IL-6 and Flt3 ligand production of bone marrow stromal cells. Zhonghua Xue Ye Xue Za Zhi 2002; 23: 585-587.
66. Weiler M, Kachko L, Chaimovitz C, et al. CD40 ligation enhances IL-15 production by tubular epithelial cells. J Am Soc Nephrol 2001; 12: 80-87. (Pubitemid 32056792)
67. Liu Z, Geboes K, Colpaert S, et al. IL-15 is highly expressed in inflammatory bowel disease and regulates local T cell-dependent cytokine production. J Immunol 2000; 164: 3608-3615. (Pubitemid 30169814)
68. Avice MN, Demeure CE, Delespesse G, et al. IL-15 promotes IL-12 production by human monocytes via T cell-dependent contact and may contribute to IL-12-mediated IFN-gamma secretion by CD4+ T cells in the absence of TCR ligation. J Immunol 1998; 161: 3408-3415.
69. Sartorius R, D'Apice L, Barba P, et al. Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presenting cells. Cell Immunol 2003; 221: 81-88. (Pubitemid 36549082)
70. Tomihara K, Kato K, Masuta Y, et al. Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells. Int J Cancer 2007; 120: 1491-1498. (Pubitemid 46355383)
71. Rey J, Veuillen C, Vey N, et al. Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors. Trends Mol Med 2009; 15: 275-284.
72. Rudin CM, Thompson CB. B-cell development and maturation. Semin Oncol 1998; 25: 435-446.
73. Duchosal MA. B-cell development and differentiation. Semin Hematol 1997; 34 (Suppl 1): 2-12.
74. Law CL, Wormann B, LeBien TW. Analysis of expression and function of CD40 on normal and leukemic human B cell precursors. Leukemia 1990; 4: 732-738. (Pubitemid 20385395)
75. Saeland S, Duvert V, Caux C, et al. Distribution of surface-membrane molecules on bone marrow and cord blood CD34+ hematopoietic cells. Exp Hematol 1992; 20: 24-33.
76. Saeland S, Duvert V, Moreau I, et al. Human B cell precursors proliferate and express CD23 after CD40 ligation. J Exp Med 1993; 178: 113-120. (Pubitemid 23173247)
77. Larson AW, LeBien TW. Cross-linking CD40 on human B cell precursors inhibits or enhances growth depending on the stage of development and the IL costimulus. J Immunol 1994; 153: 584-594.
78. Barker J, Verfaillie CM. A novel in vitro model of early human adult B lymphopoiesis that allows proliferation of pro-B cells and differentiation to mature B lymphocytes. Leukemia 2000; 14: 1614-1620.
79. Fluckiger AC, Sanz E, Garcia-Lloret M, et al. In vitro reconstitution of human B-cell ontogeny: from CD34(+) multipotent progenitors to Ig-secreting cells. Blood 1998; 92: 4509-4520.
80. Kothlow S, Morgenroth I, Tregaskes CA, et al. CD40 ligand supports the longterm maintenance and differentiation of chicken B cells in culture. Dev Comp Immunol 2008; 32: 1015-1026.
81. Funakoshi S, Taub DD, Anver MR, et al. Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice. J Clin Invest 1997; 99: 484-491. (Pubitemid 27414806)
82. Willimott S, Baou M, Naresh K, et al. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol 2007; 138: 721-732. (Pubitemid 47313210)
83. Wormann B, Gesner TG, Mufson RA, et al. Proliferative effect of interleukin-3 on normal and leukemic human B cell precursors. Leukemia 1989; 3: 399-404. (Pubitemid 19145297)
84. Pandrau D, Saeland S, Duvert V, et al. Interleukin 4 inhibits in vitro proliferation of leukemic and normal human B cell precursors. J Clin Invest 1992; 90: 1697-1706.
85. Karagogeos D, Rosenberg N, Wortis HH. Early arrest of B cell development in nude, X-linked immune-deficient mice. Eur J Immunol 1986; 16: 1125-1130. (Pubitemid 16008084)
86. Sprent J, Bruce J. Physiology of B cells in mice with X-linked immunodeficiency. II. Influence of the thymus and mature T cells on B cell differentiation. J Exp Med 1984; 160: 335-340. (Pubitemid 14089803)
87. Karagogeos D, Wortis HH. Thymus grafts induce B cell development in nude, X-linked immune deficient mice. Eur J Immunol 1987; 17: 141-144. (Pubitemid 17039341)
88. Renard N, Duvert V, Blanchard D, et al. Activated CD4+ T cells induce CD40-dependent proliferation of human B cell precursors. J Immunol 1994; 152: 1693-1701. (Pubitemid 24075699)
89. Nolte MA, Arens R, van Os R, et al. Immune activation modulates hematopoiesis through interactions between CD27 and CD70. Nat Immunol 2005; 6: 412-418. (Pubitemid 41716782)
90. Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell 2000; 100: 157-168. (Pubitemid 30046304)
91. Lai AY, Kondo M. T and B lymphocyte differentiation from hematopoietic stem cell. Semin Immunol 2008; 20: 207-212.
92. Lutgens E, Lievens D, Beckers L, et al. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med 2007; 17: 118-123.
93. Hixon JA, Blazar BR, Anver MR, et al. Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 2001; 7: 136-143.
94. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 2008; 8: 290-301.
95. Liaw L, Skinner MP, Raines EW, et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995; 95: 713-724.
96. Broxmeyer HE. Chemokines in hematopoiesis. Curr Opin Hematol 2008; 15: 49-58.
97. Arai F, Hirao A, Suda T. Regulation of hematopoiesis and its interaction with stem cell niches. Int J Hematol 2005; 82: 371-376. (Pubitemid 46638683)
98. Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004; 118: 149-161. (Pubitemid 38962572)
99. Tjwa M, Sidenius N, Moura R, et al. Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells. J Clin Invest 2009; 119: 1008-1018.
100. Kim KW, Cho ML, Kim HR, et al. Up-regulation of stromal cell-derived factor 1 (CXCL12) production in rheumatoid synovial fibroblasts through interactions with T lymphocytes: role of interleukin-17 and CD40L-CD40 interaction. Arthritis Rheum 2007; 56: 1076-1086.
101. Kassmer SH, Niggemann B, Punzel M, et. Cytokine combinations differentially influence the SDF-1alpha-dependent migratory activity of cultivated murine hematopoietic stem and progenitor cells. Biol Chem 2008; 389: 863-872.
102. Solanilla A, Dechanet J, El Andaloussi A, et al. CD40-ligand stimulates myelopoiesis by regulating flt3-ligand and thrombopoietin production in bone marrow stromal cells. Blood 2000; 95: 3758-3764. (Pubitemid 30412847)
103. Wadhwa M, Thorpe R. Haematopoietic growth factors and their therapeutic use. Thromb Haemost 2008; 99: 863-873. (Pubitemid 351705302)
104. Pyrovolaki K, Mavroudi I, Sidiropoulos P, et al. Increased expression of CD40 on bone marrow CD34+ hematopoietic progenitor cells in patients with systemic lupus erythematosus: contribution to Fas-mediated apoptosis. Arthritis Rheum 2009; 60: 543-552.
105. Callard RE, Armitage RJ, Fanslow WC, et al. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol Today 1993; 14: 559-564. (Pubitemid 23316716)
106. Subauste CS. CD154 and type-1 cytokine response: from hyper IgM syndrome to human immunodeficiency virus infection. J Infect Dis 2002; 185 (Suppl 1): S83-89.
107. Leiva LE, Junprasert J, Hollenbaugh D, et al. Central nervous system toxoplasmosis with an increased proportion of circulating gamma delta T cells in a patient with hyper-IgM syndrome. J Clin Immunol 1998; 18: 283-290. (Pubitemid 28374067)
108. Jesus AA, Duarte AJ, Oliveira JB. Autoimmunity in hyper-IgM syndrome. J Clin Immunol 2008; 28 (Suppl 1): S62-66.
109. Herve M, Isnardi I, Ng YS, et al. CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance. J Exp Med 2007; 204: 1583-1593. (Pubitemid 47048025)
110. Rathmell JC, Townsend SE, Xu JC, et al. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 1996; 87: 319-329.
111. Ostenstad B, Giliani S, Mellbye OJ, et al. A boy with X-linked hyper-IgM syndrome and natural killer cell deficiency. Clin Exp Immunol 1997; 107: 230-234. (Pubitemid 27049246)
112. Facchetti F, Appiani C, Salvi L, et al. Immunohistologic analysis of ineffective CD40-CD40 ligand interaction in lymphoid tissues from patients with X-linked immunodeficiency with hyper-IgM. Abortive germinal center cell reaction and severe depletion of follicular dendritic cells. J Immunol 1995; 154: 6624-6633.
113. Kawabe T, Naka T, Yoshida K, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994; 1: 167-178.
114. Kasran A, Boon L, Wortel CH, et al. Safety and tolerability of antagonist antihuman CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005; 22: 111-122. (Pubitemid 41039699)
115. Howard LM, Miga AJ, Vanderlugt CL, et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 1999; 103: 281-290.
116. Gruss HJ, Herrmann F, Gattei V, et al. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk Lymphoma 1997; 24: 393-422. (Pubitemid 27182198)
117. Hock BD, McKenzie JL, Patton NW, et al. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer 2006; 106: 2148-2157. (Pubitemid 43673236)
118. Blair PJ, Riley JL, Harlan DM, et al. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000; 191: 651-660.
119. Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr Opin Investig Drugs 2009; 10: 579-587.
120. Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009; 114: 1150-1157.
121. Renaudineau Y, Devauchelle-Pensec V, Hanrotel C, et al. Monoclonal anti-CD20 antibodies: mechanisms of action and monitoring of biological effects. Joint Bone Spine 2009; 76: 458-463.